Analysts said the deal shows Roche’s long-term strategy for its sequencing technology is “a clinical box for running NGS kits ...

The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.

Illumina, Inc. (ILMN) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 9:20 AM ESTCompany ParticipantsJacob Thaysen - CEO ...

Roche will receive rights to at least 1 billion lateral flow tests annually from Sapphiros as well as access to the company's future molecular testing technology.

Freenome has announced a strategic agreement with Roche aimed at commercialising its cancer screening technology outside the ...

Exact Sciences stock has recently seen its consensus analyst price target climb significantly, from around $70 to $82.10. This reflects renewed confidence in the company’s long-term value and ...

Brisbane-based Freenome has locked in a second major partnership for its blood-based cancer screening test, this time with a ...

Freenome, an early cancer detection company developing blood-based screening tests, today announced a strategic collaboration agreement with Roche to commercialize Freenome's cancer screening ...

Exact Sciences views both its Cologuard Plus test and the colorectal cancer blood test from Freenome as additive to its growth prospects, according to BTIG’s research note. In other recent news, Exact ...

If you have dry skin, you might have heard of hyaluronic acid as a solution — but with so many skin care ingredients becoming buzzwords, from retinol to vitamin C, we don’t blame you if you don’t know ...

(MENAFN- GlobeNewsWire - Nasdaq) Key opportunities in the AI clinical genomics interpretation market include the rising demand for precision medicine, wider adoption of AI-powered tools, advancements ...